This article describes the work of the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit organization founded in 2003 to develop drugs for the treatment of human African trypanosomiasis, Chagas disease, visceral leishmaniasis and malaria by initiating and coordinating drug research and development projects in collaboration with the international research community, the public sector, the pharmaceutical industry, and other relevant partners. The identification of potentially useful compounds and their development into candidate drugs are described. Several candidate compounds have been identified and are moving towards preclinical and clinical development.
Chatelain, E.; Ioset, J.R. Drug discovery and development for neglected diseases: the DNDiii model. Preclinical Drug Development (2009) : 53-60. [Special issue: Genesis 2009. In focus: Public-private partnerships in neglected diseases.]